Abstract 3657
Background
Breast cancer is the most commonly occurring cancer in women and is the leading cause of cancer death in women in Brazil. Despite being widely studied, it is a disease that is not yet fully understood in its complexity. On the other hand, changes in parkin (parkin RBR E3 ubiquitin protein ligase) expression patterns have been described in several diseases, including breast cancer. Nevertheless, the association of these changes with cancer prognostic and predictive factors remains unclear. Also, parkin regulates APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1), a protein crucial for repair of oxidized DNA damage, and BCL2L1 (BCL2 like 1), an apoptotic regulator. Both proteins were related to breast cancer.
Methods
Immunohistochemical analysis of Parkin, APEX1 and BCL2L1expression were performed in different breast cancer ductal invasive samples from Southern Brazilian patients to characterize their patterns and explore its association with clinical features and disease outcome.Therefore, 112 samples were organized into 15 Tissue Micro Arrays. The samples were classified in four molecular subtypes based on clinicopathological criteria (46 Luminal B, 24 Luminal A, 24 Basal and 18 HER2). These samples were obtained from Hospital Nossa Senhora das Graças (Curitiba, PR, Brazil) patients who were followed from 5 to 18 years.
Results
Parkin, APEX1 and BCL2L1 showed different expression patterns between the subtypes assessed. While in Luminal A and B APEX1 expression was increased, parkin expression was higher among Basal and HER2 subtypes. BCL2L1 expression was increased mainly in HER2 subtype. When regarding to estrogen (ER) and progesterone (PR) receptors, APEX1 was more expressed in ER/PR-positive samples, whereas Parkin and BCL2L1 in negative ones. No such difference was observed considering only HER2. BCL2L1 expression pattern was significantly associated with disease-free survival time independent of molecular subtypes, lymph node status and tumor size (p = 0.020). The higher the expression levels of BCL2L1, the shorter the disease-free survival time.
Conclusions
The expression of BCL2L1 is direclty associated with relapse of ductal invasive breast tumors, independently of other clinical variables.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pontifícia Universidade Católica do Paraná (PUCPR).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract